Replies to post #399879 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Which is why it would really good to know the n of the Odds Ratio responders.

Treatment by 273 for 1 year leads to worsening of ADAS-Cog by 2.36 points, right onto the placebo line.

Having time point charts of each P2b/3 outcome measure incl ADL, would be really good too.

Anavex and their new ex-FDA biostatistician should be able to do that in a couple of days - what have they been doing since 1st Dec one wonders?

Without than n etc, the $AVXL P2b/3 results are just as meaningless as SAVA's open label results and pumper's imagination.

But we are doing than Carl!

[frrol]

Worsens by 2.26, but yes. This is why you ignore pumpers, and you don't blindly take company views. Always look at trial results carefully and objectively.

And our overall ADAS scores were an improvement over our placebo arm.

[Rubyred77]

I’ll say the same thing about the sava open label data that was said when Anavex ran the same type trial.

Meaningless